Skip to main content

Kymera Therapeutics, Inc. (KYMR)

NASDAQ: KYMR · Delayed Price · USD
62.95 -1.95 (-3.00%)
Sep 17, 2021 4:00 PM EDT - Market closed
Market Cap3.03B
Revenue (ttm)34.03M
Net Income (ttm)-58.41M
Shares Out51.04M
EPS (ttm)-1.51
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,169,960
Open64.20
Previous Close64.90
Day's Range58.13 - 64.20
52-Week Range27.65 - 91.92
Betan/a
AnalystsBuy
Price Target78.43 (+24.6%)
Est. Earnings DateNov 5, 2021

About KYMR

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the...

IndustryBiotechnology
IPO DateAug 21, 2020
Employees112
Stock ExchangeNASDAQ
Ticker SymbolKYMR
Full Company Profile

Financial Performance

In 2020, KYMR's revenue was $34.03 million, an increase of 1,059.99% compared to the previous year's $2.93 million. Losses were -$45.59 million, 10.5% more than in 2019.

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for KYMR stock is "Buy." The 12-month stock price forecast is 78.43, which is an increase of 24.59% from the latest price.

Price Target
$78.43
(24.59% upside)
Analyst Consensus: Buy

News

Kymera Therapeutics to Present at Upcoming September Investor Conferences

WATERTOWN, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small mo...

2 weeks ago - GlobeNewsWire

Kymera Therapeutics Announces Second Quarter 2021 Financial Results and Provides a Business Update

Positive interim results from Single Ascending Dose portion of Phase 1 trial of first-in-class oral IRAK4 degrader KT-474 demonstrated degrader proof-of-mechanism

1 month ago - GlobeNewsWire

Kymera Therapeutics Presents New Preclinical Data on STAT3 Degraders Showing Antitumor Activity in STAT3 Mutant and W...

Data demonstrate Kymera's ability to degrade mutant and wild-type STAT3, a traditionally “undruggable” target, and the broad therapeutic potential for the treatment of peripheral T-cell lymphoma subtype...

2 months ago - GlobeNewsWire

Kymera Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' O...

WATERTOWN, Mass., July 06, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small mol...

2 months ago - GlobeNewsWire

Kymera Prices $223M Equity Offering At $47/Share

Kymera Therapeutics Inc (NASDAQ: KYMR) has priced its upsized underwritten public offering of 4.7 million shares at $47.00 per share, representing a discount of 3% from the last close price of $48.5 on ...

2 months ago - Benzinga

Kymera Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

WATERTOWN, Mass., June 30, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small mol...

2 months ago - GlobeNewsWire

Kymera Therapeutics Seeks To Raise Capital Via 4M Shares Equity Offering To Fund Oncology Franchises

Kymera Therapeutics Inc (NASDAQ: KYMR) commenced an underwritten public offering of 4 million shares of common stock.  Underwriters can purchase up to an additional 600k shares.

2 months ago - Benzinga

Kymera Therapeutics Announces Proposed Public Offering of Common Stock

WATERTOWN, Mass., June 28, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small mol...

2 months ago - GlobeNewsWire

Kymera's KT-474 Achieved Sustained IRAK4 Reduction After Single Dose In Healthy Volunteers

Kymera Therapeutics Inc (NASDAQ: KYMR) has announced interim results from the Single Ascending Dose (SAD) portion of the Phase 1 trial of KT-474 in healthy volunteers. KT-474 has exceeded the Phase 1 ta...

2 months ago - Benzinga

Kymera Therapeutics Announces Positive Interim Results from Single Ascending Dose Phase 1 Trial of KT-474 Demonstrati...

KT-474 has achieved and exceeded Phase 1 target degradation of 85% within the SAD portion of the Phase 1 trial dosed to date, with 90% median degradation at the 300 mg dose

2 months ago - GlobeNewsWire

Kymera Therapeutics Appoints Elaine Caughey, MBA, as Chief Business Officer

WATERTOWN, Mass., June 21, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small mol...

2 months ago - GlobeNewsWire

Kymera Therapeutics' KT-413 Shows Encouraging Preclinical Anti-Cancer Activity

Kymera Therapeutics Inc (NASDAQ: KYMR) has announced new preclinical data on its IRAKIMiD degrader KT-413's potential as both a monotherapy and in combination with other anticancer agents. The data were...

2 months ago - Benzinga

Kymera Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference

WATERTOWN, Mass., June 02, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small mol...

3 months ago - GlobeNewsWire

Kymera Therapeutics Presents New Data Demonstrating Proof-of-Degradation Using Novel Tissue-Restricted E3 Ligase

Novel E3 ligase identified by Kymera's Whole-Body Atlas is expressed in selected tissues while broadly expressed in cancer cells

3 months ago - GlobeNewsWire

Kymera Therapeutics Presents Late-Breaking Preclinical Data on IRAK4 Degrader KT-474 at IMMUNOLOGY2021™ Annual Meeting

New in vivo data demonstrate the broad anti-inflammatory activity of KT-474 and its superiority compared to a clinically active small molecule IRAK4 kinase inhibitor in preclinical immune-inflammatory m...

4 months ago - GlobeNewsWire

Kymera Therapeutics Announces First Quarter 2021 Financial Results and Provides a Business Update

Phase 1 trial of first-in-class oral IRAK4 degrader KT-474 initiated in February; on track to present human proof-of-biology data in 4Q 2021

4 months ago - GlobeNewsWire

Kymera Therapeutics to Present at Upcoming May Investor Conferences

WATERTON, Mass., May 04, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molec...

4 months ago - GlobeNewsWire

Kymera Therapeutics to Present New In Vivo Data Demonstrating the Broad Anti-Inflammatory Activity of its IRAK4 Degra...

Data demonstrate KT-474's superiority compared to a clinically active small molecule IRAK4 kinase inhibitor across a wide variety of immune-inflammatory preclinical models Data demonstrate KT-474's supe...

4 months ago - GlobeNewsWire

Kymera Therapeutics Honored by Boston Business Journal as a 2021 Best Places to Work Company

WATERTOWN, Mass., April 19, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small mo...

4 months ago - GlobeNewsWire

Kymera Therapeutics Presents Late-Breaking Preclinical Data Highlighting Superiority of Dual-Targeting Activity of IR...

KT-413-mediated degradation of IRAK4 and IMiD substrates has synergistic effect on MYD88-NFkB and IRF4-Type 1 Interferon pathways resulting in superior antitumor activity in MYD88-mutant DLBCL models co...

5 months ago - GlobeNewsWire

Kymera Therapeutics to Present New Results from Non-Interventional Study in Patients with Hidradenitis Suppurativa at...

WATERTOWN, Mass., April 09, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small mo...

5 months ago - GlobeNewsWire

Kymera Therapeutics Appoints Elena Ridloff, CFA, to Board of Directors

WATERTOWN, Mass., March 16, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small mo...

6 months ago - GlobeNewsWire

Kymera Therapeutics Announces First-in-Human Dose in Phase 1 Trial of KT-474, a First-in-Class IRAK4 Protein Degrader...

KT-474 is the first IRAK4 degrader, and first heterobifunctional small molecule protein degrader outside of oncology, to enter clinical development

6 months ago - GlobeNewsWire

Kymera Therapeutics to Present at Upcoming March Investor Conferences

WATERTOWN, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein d...

6 months ago - GlobeNewsWire

Kymera Therapeutics Strengthens Leadership with Key Appointments and Promotions

WATERTOWN, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein d...

7 months ago - GlobeNewsWire